NLRC5/CITA: A Key Player in Cancer Immune Surveillance
| Autor: | Saptha Vijayan, Sayuri Yoshihama, Koichi Kobayashi, Tabasum Sidiq |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
0301 basic medicine
Cancer Research Genes MHC Class I chemical and pharmacologic phenomena Biology Article 03 medical and health sciences Transactivation 0302 clinical medicine Immune system Neoplasms NLRC5 MHC class I Biomarkers Tumor medicine Animals Humans Cytotoxic T cell Immunologic Surveillance MHC Class I Gene Intracellular Signaling Peptides and Proteins Cancer Prognosis medicine.disease Gene Expression Regulation Neoplastic 030104 developmental biology Oncology Immunology Cancer cell biology.protein 030215 immunology |
| Zdroj: | Trends in Cancer. 3:28-38 |
| ISSN: | 2405-8033 |
| Popis: | Cancer cells need to escape immune surveillance for successful tumor growth. Loss of MHC class I has been described as a major immune evasion strategy in many cancers. MHC class I transactivator (CITA), NLRC5 [nucleotide-binding domain and leucine-rich repeats containing (NLR) family, caspase activation and recruitment domain (CARD) domain containing 5], is a key transcription coactivator of MHC class I genes. Recent genetic studies have revealed that NLRC5 is a major target for cancer immune evasion mechanisms. The reduced expression or activity of NLRC5 caused by promoter methylation, copy number loss, or somatic mutations is associated with defective MHC class I expression, impaired cytotoxic T cell activation, and poor patient prognosis. Here, we review the role of NLRC5 in cancer immune evasion and the future prospects for cancer research. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|